Mesenteric vasodilation mediated by endothelial anandamide receptors

Hypertension

Volumn 33, Issue 1 II, 1999, Pages 429-434

  Wagner, Jens A ^b   Varga, Károly ^b   Járai, Zoltán ^b   Kunos, George ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Anandamide; Cannabinoids; Endotoxin; Vasodilation

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANANDAMIDE; CANNABINOID; CANNABINOID RECEPTOR ANTAGONIST; DEXANABINOL; ENDOTOXIN; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BLOOD VESSEL TONE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; LIGAND BINDING; LONG TERM POTENTIATION; MACROPHAGE ACTIVATION; MESENTERIC ARTERY; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; VASCULAR SMOOTH MUSCLE; VASODILATATION;

EID: 0032924113     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.33.1.429     Document Type: Article

References (38)

1. Mechoulam R, Shabat SB, Hanus L, Fride E, Bayewitch M, Vogel Z. Endogenous cannabinoid ligands. Adv Exp Biol Med. 1996;402:95-101.
2. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561-564.
3. Shire D, Carillon C, Kaghad M, Calandra B, Rinaldi-Carmona M, Le Fur G, Ferrara P. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem. 1995;270: 3726-3731.
4. Ishac EJN, Jiang L, Lake KD, Varga K, Abood MA, Kunos G. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol. 1996;118:2023-2028.
5. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61-65.
6. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science. 1992;258:1946-1949.
7. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminsky NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995;50:83-90.
8. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K. 2-Arachidonoyl-glycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995;215:89-97.
9. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz J-C, Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 1994;372:686-691.
10. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 1997;388:773-778.
11. Collin C, Devane WA, Dahl D, Lee CJ, Axelrod J, Alkon DL. Long-term synaptic transformation of hippocampal CA1 gamma-aminobutyric acid synapses and the effect of anandamide. Proc Natl Acad Sci U S A. 1995;92:10167-10171.
12. 18 neuroblastoma cells. Biochem J. 1996;316:977-984.
13. Deutsch DG, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HH, Das SK, Dey SK, Arreza G, Thorup C, Stefano G, Moore LC. Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest. 1997;100:1538-1546.
14. Wagner JA, Varga K, Ellis EF, Rzigalinski BA, Martin BR, Kunos G. Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature. 1997;390:518-521.
15. Sugiura T, Kodaka T, Nakane S, Kishimoto S, Kondo S, Waku K. Detection of an endogenous cannabimimetic molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells: is 2-arachidonoylglycerol a possible vasomodulator? Biochem Biophys Res Commun. 1998;243:838-843.
16. Varga K, Wagner JA, Bridgen DT, Kunos G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J. 1998;12:1035-1044.
17. 9-trans-tetrahydrocannabinol. J Pharm Pharmacol. 1974;26:186-198.
18. Varga K, Lake K, Martin BR, Kunos G. Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol. 1995;278:279-283.
19. Varga K, Lake KD, Huangfu D, Guyenet P, Kunos G. Mechanism of the hypotensive action of anandamide in anesthetized rats Hypertension 1996;28:682-688.
20. Calignano A, La Rana G, Beltramo M, Makryannis A, Piomelli D. Potentiation of anandamide hypotension by the transport inhibitor, AM404. Eur J Pharmacol. 1997;337:R1-R2.
21. Malinowska B, Godlewski G, Bucher B, Schlicker E. Cannabinoid CB1 receptor-mediated inhibition of the neurogenic vasopressor response in the pithed rat. Naunyn Schmiedebergs Arch Pharmacol. 1997;356:197-202.
22. 1-like cannabinoid receptors. J Pharmacol Exp Ther. 1997;281:1030-1037.
23. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Marani J, Néliat G, Caput D, Ferrara P, Soubrié P, Brelière JC, Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994;350:240-244.
24. Randall MD, Alexander SPH, Bennett T, Boyd EA, Fry JR, Gardiner SM, Kemp PA, McCulloch AI, Kendall DA. An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochem Biophys Res Commun. 1996;229:114-120.
25. White R, Hiley CR. A comparison of EDHF-mediated and anandamide-induced relaxations in the rat isolated mesenteric artery. Br J Pharmacol. 1997;122:1573-1584.
26. Plane F, Holland M, Waldron GJ, Garland CJ, Boyle JP. Evidence that anandamide and EDHF act via different mechanisms in rat isolated mesenteric arteries. Br J Pharmacol. 1997;121:1509-1511.
27. 1 receptor and endothelium-dependent hyperpolarization in guinea-pig carotid, rat mesenteric and porcine coronary arteries. Br J Pharmacol. 1998;123:968-974.
28. 1 cannabinoid receptor. Am J Physiol. 1998;274:H375-H381.
29. McGregor DD. The effect of sympathetic nerve stimulation on vasoconstrictor responses in perfused mesenteric blood vessels of the rat. J Physiol (Lond). 1965;177:21-30.
30. Tallarida RJ, Murray RB. Manual of Pharmacologic Calculations with Computer Programs. 2nd edition. New York, NY: Springer; 1987.
31. Abadji V, Lin S, Taha G, Griffin G, Stevenson LA, Pertwee RG, Makryannis A. (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem. 1994;37: 1889-1893.
32. Deutsch DG, Chin SA. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol. 1993;46: 791-796.
33. Lake KD, Martin BR, Kunos G, Varga K. Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension. 1997;29:1204-1210.
34. Schatz AR, Lee M, Condie RB, Pulaski JT, Kaminski NE. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol. 1997;142:278-287.
35. Showalter VM, Compton DR, Martin BR, Abood MA. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther. 1996;278:989-999.
36. Parnavelas JG, Kelly W, Burnstock G. Ultrastructural localization of choline acetyltransferase in vascular endothelial cells in rat brain. Nature. 1985;316:724-725.
37. Jara PI, Boric MP, Saez JC. Leukocytes express connexin 43 after activation with lipopolysaccharide and appear to form gap junctions with endothelial cells after ischemia-reperfusion. Proc Natl Acad Sci U S A. 1995;92:7011-7015.
38. Pugin J, Ulevitch RJ, Tobias PS. A critical role for monocytes and CD14 in endotoxin-induced endothelial cell activation. J Exp Med. 1993;178: 2193-2200.